Annual Cash & Cash Equivalents
$193.51 M
-$97.54 M-33.51%
December 31, 2023
Summary
- As of February 7, 2025, INVA annual cash & cash equivalents is $193.51 million, with the most recent change of -$97.54 million (-33.51%) on December 31, 2023.
- During the last 3 years, INVA annual cash & cash equivalents has fallen by -$52.97 million (-21.49%).
- INVA annual cash & cash equivalents is now -33.51% below its all-time high of $291.05 million, reached on December 31, 2022.
Performance
INVA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$260.63 M
+$43.63 M+20.10%
September 1, 2024
Summary
- As of February 7, 2025, INVA quarterly cash and cash equivalents is $260.63 million, with the most recent change of +$43.63 million (+20.10%) on September 1, 2024.
- Over the past year, INVA quarterly cash and cash equivalents has increased by +$80.63 million (+44.80%).
- INVA quarterly cash and cash equivalents is now -45.61% below its all-time high of $479.19 million, reached on September 30, 2020.
Performance
INVA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
INVA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.5% | +44.8% |
| 3 y3 years | -21.5% | +29.3% |
| 5 y5 years | +210.0% | +50.7% |
INVA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -33.5% | at low | -13.3% | +80.9% |
| 5 y | 5-year | -33.5% | at low | -45.6% | +502.4% |
| alltime | all time | -33.5% | +441.3% | -45.6% | +1721.3% |
Innoviva Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $260.63 M(+20.1%) |
| Jun 2024 | - | $217.00 M(+21.7%) |
| Mar 2024 | - | $178.36 M(-7.8%) |
| Dec 2023 | $193.51 M(-33.5%) | $193.51 M(+7.5%) |
| Sep 2023 | - | $180.00 M(+4.0%) |
| Jun 2023 | - | $173.03 M(+20.1%) |
| Mar 2023 | - | $144.05 M(-50.5%) |
| Dec 2022 | $291.05 M(+44.4%) | $291.05 M(-3.2%) |
| Sep 2022 | - | $300.79 M(+6.1%) |
| Jun 2022 | - | $283.58 M(+30.8%) |
| Mar 2022 | - | $216.80 M(+7.6%) |
| Dec 2021 | $201.53 M(-18.2%) | $201.53 M(+49.2%) |
| Sep 2021 | - | $135.12 M(+212.3%) |
| Jun 2021 | - | $43.27 M(-84.7%) |
| Mar 2021 | - | $282.89 M(+14.8%) |
| Dec 2020 | $246.49 M(-11.4%) | $246.49 M(-48.6%) |
| Sep 2020 | - | $479.19 M(+16.0%) |
| Jun 2020 | - | $413.15 M(+17.4%) |
| Mar 2020 | - | $351.98 M(+26.6%) |
| Dec 2019 | $278.10 M(+345.5%) | $278.10 M(+60.8%) |
| Sep 2019 | - | $172.95 M(+21.8%) |
| Jun 2019 | - | $141.95 M(+117.9%) |
| Mar 2019 | - | $65.15 M(+4.4%) |
| Dec 2018 | $62.42 M(-14.9%) | $62.42 M(+28.4%) |
| Sep 2018 | - | $48.62 M(-44.3%) |
| Jun 2018 | - | $87.23 M(+221.4%) |
| Mar 2018 | - | $27.14 M(-63.0%) |
| Dec 2017 | $73.34 M(-37.9%) | $73.34 M(-47.0%) |
| Sep 2017 | - | $138.42 M(+8.4%) |
| Jun 2017 | - | $127.63 M(-20.1%) |
| Mar 2017 | - | $159.81 M(+35.4%) |
| Dec 2016 | $118.02 M(-25.9%) | $118.02 M(+26.6%) |
| Sep 2016 | - | $93.19 M(-17.5%) |
| Jun 2016 | - | $112.94 M(-25.6%) |
| Mar 2016 | - | $151.78 M(-4.7%) |
| Dec 2015 | $159.18 M(+64.4%) | $159.18 M(+102.1%) |
| Sep 2015 | - | $78.75 M(-47.4%) |
| Jun 2015 | - | $149.58 M(+5.9%) |
| Mar 2015 | - | $141.19 M(+45.9%) |
| Dec 2014 | $96.80 M | $96.80 M(-19.0%) |
| Sep 2014 | - | $119.58 M(-42.5%) |
| Jun 2014 | - | $208.05 M(+66.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $125.28 M(-12.7%) |
| Dec 2013 | $143.51 M(+51.3%) | $143.51 M(-16.5%) |
| Sep 2013 | - | $171.89 M(-13.7%) |
| Jun 2013 | - | $199.24 M(-25.1%) |
| Mar 2013 | - | $266.07 M(+180.5%) |
| Dec 2012 | $94.85 M(+111.8%) | $94.85 M(-15.5%) |
| Sep 2012 | - | $112.23 M(-30.3%) |
| Jun 2012 | - | $161.10 M(+1025.8%) |
| Mar 2012 | - | $14.31 M(-68.0%) |
| Dec 2011 | $44.78 M(-72.6%) | $44.78 M(-28.6%) |
| Sep 2011 | - | $62.74 M(-30.8%) |
| Jun 2011 | - | $90.66 M(-38.7%) |
| Mar 2011 | - | $147.87 M(-9.5%) |
| Dec 2010 | $163.33 M(+243.5%) | $163.33 M(+158.8%) |
| Sep 2010 | - | $63.10 M(-9.5%) |
| Jun 2010 | - | $69.72 M(-36.6%) |
| Mar 2010 | - | $109.92 M(+131.2%) |
| Dec 2009 | $47.54 M(-48.5%) | $47.54 M(-27.5%) |
| Sep 2009 | - | $65.59 M(+7.4%) |
| Jun 2009 | - | $61.10 M(-16.2%) |
| Mar 2009 | - | $72.92 M(-21.0%) |
| Dec 2008 | $92.28 M(+6.8%) | $92.28 M(-28.4%) |
| Sep 2008 | - | $128.97 M(+47.2%) |
| Jun 2008 | - | $87.61 M(+7.8%) |
| Mar 2008 | - | $81.28 M(-6.0%) |
| Dec 2007 | $86.43 M(+19.4%) | $86.43 M(+9.6%) |
| Sep 2007 | - | $78.86 M(+73.1%) |
| Jun 2007 | - | $45.55 M(-41.0%) |
| Mar 2007 | - | $77.15 M(+6.6%) |
| Dec 2006 | $72.39 M(+45.4%) | $72.39 M(-15.6%) |
| Sep 2006 | - | $85.73 M(+1.0%) |
| Jun 2006 | - | $84.90 M(-18.0%) |
| Mar 2006 | - | $103.52 M(+107.9%) |
| Dec 2005 | $49.79 M(-50.9%) | $49.79 M(+122.7%) |
| Sep 2005 | - | $22.36 M(-65.0%) |
| Jun 2005 | - | $63.88 M(-25.3%) |
| Mar 2005 | - | $85.50 M(-15.7%) |
| Dec 2004 | $101.41 M(+183.7%) | $101.41 M(+166.8%) |
| Sep 2004 | - | $38.00 M(-64.2%) |
| Jun 2004 | - | $106.29 M |
| Dec 2003 | $35.75 M(-67.1%) | - |
| Dec 2002 | $108.80 M | - |
FAQ
- What is Innoviva annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Innoviva?
- What is Innoviva annual cash & cash equivalents year-on-year change?
- What is Innoviva quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Innoviva?
- What is Innoviva quarterly cash and cash equivalents year-on-year change?
What is Innoviva annual cash & cash equivalents?
The current annual cash & cash equivalents of INVA is $193.51 M
What is the all time high annual cash & cash equivalents for Innoviva?
Innoviva all-time high annual cash & cash equivalents is $291.05 M
What is Innoviva annual cash & cash equivalents year-on-year change?
Over the past year, INVA annual cash & cash equivalents has changed by -$97.54 M (-33.51%)
What is Innoviva quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of INVA is $260.63 M
What is the all time high quarterly cash and cash equivalents for Innoviva?
Innoviva all-time high quarterly cash and cash equivalents is $479.19 M
What is Innoviva quarterly cash and cash equivalents year-on-year change?
Over the past year, INVA quarterly cash and cash equivalents has changed by +$80.63 M (+44.80%)